NCT05229536View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

PHASE2CompletedINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

November 21, 2019

Study Completion Date

November 21, 2019

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.

BIOLOGICAL

Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.

Trial Locations (1)

530028

Rongan Center for Disease Control and Prevention, Liuzhou

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY

NCT05229536 - Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months | Biotech Hunter | Biotech Hunter